Primary central nervous system lymphoma

Gelabert-González, Miguel; Bouzas, D. Castro; Serramito-García, R.; Dantas, C. Frieiro; Echabe, E. Aran

doi:10.1016/j.nrleng.2012.04.015

Cited by 6 publications

(5 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2016; 3(2):e32127. Most research on this topic has been performed on small sample sizes, but this study benefitted from a comparatively larger sample size (17,18). The demographic results, including mean age and the male-to-female ratio, were similar to those of studies by Makino et al in 2006 andRubenstein et al in 2008 (19, 20).…”

supporting

confidence: 75%

Clinical Presentations of 176 Cases of Primary Central Nervous System Lymphoma: A Case Series

et al. 2015

View full text Add to dashboard Cite

Background: Primary central nervous system lymphoma (PCNSL) is a malignant tumor, the incidence of which has been increasing in immune compromised patients during the last two decades. Objectives: This study was conducted to determine the most prevalent clinical presenting symptoms of PCNSL patients. Patients and Methods: In this retrospective descriptive study, all PCNSL patients' data over a 25-year period (1990-2014) were assessed. PCNSL was confirmed pathologically after stereotactic biopsy in the Neurosurgery Department of Shohadaye Tajrish Hospital, Tehran, Iran. Results: A total of 176 cases of PCNSL were enrolled. There were 107 (60.8%) male patients, with a 1.5:1 male: female ratio. The patients most commonly presented in the sixth decade of their lives, with a mean age of 47 ± 1.5 years. The most common presenting symptoms were hemiparesis (56.2%) and headache (51.7%). The periventricular white matter (51.1%) and basal ganglion (48.9%) were the most common sites of involvement, and they frequently affected the supratentorial area (84.7%). Conclusions: Based on the data from this study, hemiparesis and headache were the most prevalent clinical presenting symptoms of PCNSL. Cognitive impairment and personality changes were also common in these patients.

show abstract

supporting

confidence: 75%

Clinical Presentations of 176 Cases of Primary Central Nervous System Lymphoma: A Case Series

et al. 2015

View full text Add to dashboard Cite

show abstract

“…CT and MRI scan generally provide results suggestive but not conclusive for PCNSL (Koeller et al, 1997;Herrlinger et al, 1999). 2005; Zhang et al, 2010;Gelabert-González et al, 2012). A nationwide survey of PCNSL in Japan during the period 2000-2004 revealed that T-cell PCNSL accounted for 1.7% of all cases (Shibamoto et al, 2008), whereas a similar earlier study (1985)(1986)(1987)(1988)(1989)(1990)(1991)(1992)(1993)(1994) from the same country showed a higher figure of 8.5% (Hayabuchi et al, 1999).…”

Section: Discussionmentioning

confidence: 90%

Primary Central Nervous System Lymphoma: A Clinicopathological and Cytomorpholgical Study from A Tertiary Care Centre in Chennai, India

Ambroise

Ghosh²,

Mallikarjuna³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The aim of this study was to analyze the clinicopathological and immunohistochemical features of primary central nervous system lymphoma (PCNSL) cases occurring in Indian patients and also study the utility of the crush smear preparation in intraoperative diagnosis. Materials and Methods: The immune status, clinical, radiological details, immunohistochemical profile, histopathological findings and cytological features in smear preparation of 32 cases of PCNSL were analyzed. Patients with systemic NHL and skull-base lymphomas were excluded. Results: The mean age of our patients was 52 years with a male: female ratio 1:1. A periventricular location was found in 62.5% of patients. None of our PCNSL cases were associated with AIDS. All cases except one were diffuse large B-cell lymphomas. Intraoperative diagnosis using crush smears allowed correct prediction in 93% of cases. Conclusions: Our study shows that PCNSL is seen predominantly in immunocompetent patients in India .The age of presentation is relatively young as compared to the West. Our study also stresses the utility of crush smear preparation in establishing an intraoperative diagnosis.

show abstract

“…Statistical data from the United States of America between 2000-2004 revealed that the average age of patients diagnosed with PCNSL was 60 years, and the age of the majority of patients ranged within 50-65 years (5,33,34). A study conducted in Spain revealed that within the period 1990-2010, the average age of patients diagnosed with PCNSL was 59.3 years (35). In the present study, the average age of patients was 53.5 years, which was decreased compared with that in other countries.…”

Section: Discussionmentioning

confidence: 99%

“…The clinical symptoms of patients with PCNSL were associated with the location of tumor lesions (37,38). A study in Spain revealed that patients with cognitive function decline accounted for 33.4%, and those with cephalea accounted for 25% (35). The present study revealed that increased intracranial pressure and physical movement disorders were common, and the rates for the two symptoms were 53.6%; followed by cognitive dysfunction (33.9%), vision impairment (30.3%) and language disorder (17.9%).…”

Section: Discussionmentioning

confidence: 99%

Curative effect of methotrexate combined with teniposide in the treatment of primary central nervous system lymphoma

Wang

Huang

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

The present study aimed to investigate the curative effect of high-dose methotrexate (HD-MTX) combined with teniposide (Vm26) vs. HD-MTX alone in the treatment of primary central nervous system lymphoma (PCNSL), in order to provide data for assisting decisions associated with clinical treatment. Data from 56 patients with PCNSL admitted in Shanghai Huashan Hospital (Shanghai, China) from January 2009 to December 2014 were included into the present study. Clinical data, curative effects and prognosis of patients in these two groups were retrospectively analyzed using SPSS 20 statistical software. In the HD-MTX+Vm26 group, 12 patients (42.85%) achieved complete remission (CR) and 10 patients (35.71%) achieved partial remission (PR), while in the HD-MTX group 7 patients (25%) achieved CR and 11 patients (39.29%) achieved PR (P=0.158). The median progression-free survival (PFS) time was 22 months in the HD-MTX+Vm26 group and 12 months in the HD-MTX group (P=0.019). The median overall survival time was 57 months in the HD-MTX+Vm26 group, and 28 months in the HD-MTX group (P=0.013). Compared with HD-MTX alone, the combined treatment of HD-MTX+Vm26 had an improved curative effect in the treatment of PCNSL, effectively controlled tumor progression in patients, prolonged survival time and improved prognosis. Age was an independent prognostic factor in patients with PCNSL. Patients with an age of ≤60 years exhibited longer PFS compared with patients with an age of >60 years.

show abstract

Primary central nervous system lymphoma

Cited by 6 publications

References 57 publications

Clinical Presentations of 176 Cases of Primary Central Nervous System Lymphoma: A Case Series

Clinical Presentations of 176 Cases of Primary Central Nervous System Lymphoma: A Case Series

Primary Central Nervous System Lymphoma: A Clinicopathological and Cytomorpholgical Study from A Tertiary Care Centre in Chennai, India

Curative effect of methotrexate combined with teniposide in the treatment of primary central nervous system lymphoma

Contact Info

Product

Resources

About